Abstract
Huntington disease (HD) is an autosomal neurodegenerative disease caused by the excess of CAG trinucleotide repeats in the Huntington gene (HTT). In addition to various symptoms such as chorea, movement disorders, cognitive impairment and psychosis, patients with HD may also experience behavioral and physical changes. Although there is no known cure for HD, there are many ways to try to reduce symptoms and slow the progression of the disease. Medications such as tetrabenazine and tetrabenazine target physical symptoms by reducing movement. Antidepressants and antipsychotics are also used to manage the psychotic and cognitive symptoms of HD. The purpose of this review is to discuss the effectiveness of current HD treatments and explore the progress in clinical research on emerging HD treatments.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have